Insider Selling: Outset Medical, Inc. (NASDAQ:OM) General Counsel Sells $16,598.52 in Stock

Outset Medical, Inc. (NASDAQ:OM) General Counsel John L. Brottem sold 20,492 shares of the company’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $0.81, for a total transaction of $16,598.52. Following the transaction, the general counsel now owns 205,028 shares of the company’s stock, valued at approximately $166,072.68. The trade was a 9.09 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Outset Medical Stock Down 6.1 %

Shares of OM stock opened at $0.76 on Thursday. Outset Medical, Inc. has a one year low of $0.44 and a one year high of $5.22. The company has a debt-to-equity ratio of 4.12, a current ratio of 6.49 and a quick ratio of 5.04. The stock has a fifty day moving average price of $1.01 and a 200 day moving average price of $1.39. The stock has a market cap of $40.06 million, a P/E ratio of -0.28 and a beta of 2.05.

Hedge Funds Weigh In On Outset Medical

Hedge funds and other institutional investors have recently made changes to their positions in the business. Millennium Management LLC lifted its position in shares of Outset Medical by 58.8% during the 2nd quarter. Millennium Management LLC now owns 1,942,899 shares of the company’s stock worth $7,480,000 after buying an additional 719,412 shares during the period. Massachusetts Financial Services Co. MA lifted its holdings in shares of Outset Medical by 118.5% during the second quarter. Massachusetts Financial Services Co. MA now owns 1,538,859 shares of the company’s stock valued at $5,925,000 after acquiring an additional 834,663 shares during the period. GSA Capital Partners LLP boosted its stake in shares of Outset Medical by 924.7% in the 3rd quarter. GSA Capital Partners LLP now owns 1,111,612 shares of the company’s stock valued at $753,000 after purchasing an additional 1,003,135 shares in the last quarter. Marshall Wace LLP grew its holdings in shares of Outset Medical by 487.8% in the 2nd quarter. Marshall Wace LLP now owns 314,187 shares of the company’s stock worth $1,210,000 after purchasing an additional 260,740 shares during the last quarter. Finally, Point72 Asset Management L.P. acquired a new stake in shares of Outset Medical during the 2nd quarter worth about $827,000.

Analysts Set New Price Targets

Separately, Royal Bank of Canada reiterated a “sector perform” rating and issued a $3.00 target price on shares of Outset Medical in a research note on Tuesday, January 7th.

About Outset Medical

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.